We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Humana (HUM - Free Report) closed at $487.03, marking a +0.76% move from the previous day. This move outpaced the S&P 500's daily loss of 1.15%. Meanwhile, the Dow lost 0.52%, and the Nasdaq, a tech-heavy index, lost 0.34%.
Heading into today, shares of the health insurer had gained 8.82% over the past month, outpacing the Medical sector's gain of 0.72% and the S&P 500's loss of 5.08% in that time.
Humana will be looking to display strength as it nears its next earnings release, which is expected to be July 27, 2022. In that report, analysts expect Humana to post earnings of $7.67 per share. This would mark year-over-year growth of 11.32%. Our most recent consensus estimate is calling for quarterly revenue of $23.39 billion, up 13.31% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $24.65 per share and revenue of $93.09 billion. These totals would mark changes of +19.43% and +12.08%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Humana. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Humana is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Humana's current valuation metrics, including its Forward P/E ratio of 19.61. This represents a premium compared to its industry's average Forward P/E of 16.6.
Meanwhile, HUM's PEG ratio is currently 1.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. HUM's industry had an average PEG ratio of 1.1 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 22, which puts it in the top 9% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Gains As Market Dips: What You Should Know
In the latest trading session, Humana (HUM - Free Report) closed at $487.03, marking a +0.76% move from the previous day. This move outpaced the S&P 500's daily loss of 1.15%. Meanwhile, the Dow lost 0.52%, and the Nasdaq, a tech-heavy index, lost 0.34%.
Heading into today, shares of the health insurer had gained 8.82% over the past month, outpacing the Medical sector's gain of 0.72% and the S&P 500's loss of 5.08% in that time.
Humana will be looking to display strength as it nears its next earnings release, which is expected to be July 27, 2022. In that report, analysts expect Humana to post earnings of $7.67 per share. This would mark year-over-year growth of 11.32%. Our most recent consensus estimate is calling for quarterly revenue of $23.39 billion, up 13.31% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $24.65 per share and revenue of $93.09 billion. These totals would mark changes of +19.43% and +12.08%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Humana. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Humana is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Humana's current valuation metrics, including its Forward P/E ratio of 19.61. This represents a premium compared to its industry's average Forward P/E of 16.6.
Meanwhile, HUM's PEG ratio is currently 1.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. HUM's industry had an average PEG ratio of 1.1 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 22, which puts it in the top 9% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.